---
title: "Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288903656.md"
description: "Vertex Pharmaceuticals (VRTX) stock rose 1.15% to $446.83, outperforming the broader market and competitors on a poor trading day. The S&P 500 fell 2.64%, while peers like AbbVie gained slightly and Krystal Biotech dropped. VRTX marked its third consecutive gain, closing 12.03% below its 52-week high of $507.92. Trading volume reached 1.5 million shares, exceeding the 50-day average."
datetime: "2026-06-05T20:37:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288903656.md)
  - [en](https://longbridge.com/en/news/288903656.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288903656.md)
---

# Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. (VRTX) advanced 1.15% to $446.83 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 2.64% to 7,383.74 and Dow Jones Industrial Average falling 1.35% to 50,866.78.

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals Inc. closed 12.03% short of its 52-week high of $507.92, which the company achieved on March 10th.

The stock outperformed some of its competitors Friday, as AbbVie Inc. (ABBV) rose 1.02% to $227.23, Krystal Biotech Inc. (KRYS) fell 2.21% to $301.00, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 9.20% to $7.30.

Trading volume (1.5 M) eclipsed its 50-day average volume of 1.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled June 5, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

06-05-26 1637ET

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)
- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference | VRTX Stock News](https://longbridge.com/en/news/288887349.md)
- [Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?](https://longbridge.com/en/news/288312641.md)
- [Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 | VRTX Stock News](https://longbridge.com/en/news/288621138.md)
- [Vertex Extends Cystic Fibrosis Reach With Pediatric ALYFTREK And TRIKAFTA Data](https://longbridge.com/en/news/289199131.md)
- [Waterloo Capital L.P. Invests $1.78 Million in Vertex Pharmaceuticals Incorporated $VRTX](https://longbridge.com/en/news/288260787.md)